About this trial
The purpose of this study aimed to compare the efficacy of Oxiris (Baxter) and M100 filters on IL-6 as primary outcomes and other blood cell counts, blood biochemistry (serum urea, creatinine, potassium, sodium), inflammation indicators (CRP, PCT), as secondary outcomes and safety (28 days mortality as a primary outcome and coagulopathy, lifespan of filter, usage of vasopressor, clinical conditions (ventilator-free days, ICU and hospital- length of stay) as a secondary outcome), clinical conditions (ventilator-free days, ICU and hospital- length of stay), and mortality of patients with pneumonia-related AKI.
Eligibility criteria
Qualifiers
All adult patients aged>18 years old
Diagnosis of septic shock
Diagnosis of KDIGO stage 3 acute renal failure
Disqualifiers
Moribund patient or patient that is expected to die within 72 hours
Pregnancy
patient with a bleeding tendency or known allergy to heparin
Trial design
Treatments tested in this trial
- oXiris filter
- M100 filter
Treatment groups
Sponsors and collaborators
Mohd Zulfakar Mazlan, MBBS
Lead sponsor
Universiti Sains Malaysia
Sponsor institution